Brief: Eloxx Pharmaceuticals Intends To Advance ELX-02 Into Pivotal Trial For The Treatment Of Alport Syndrome With Nonsense Mutations
24/05/2023 13:12
May 24 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O :
* ELOXX PHARMACEUTICALS INTENDS TO ADVANCE ELX-02 INTO
PIVOTAL
TRIAL FOR THE TREATMENT OF ALPORT SYNDROME WITH NONSENSE
MUTATIONS FOLLOWING ACHIEVEMENT OF REMISSION IN PATIENT IN PHASE
2 STUDY
* ELOXX PHARMACEUTICALS INTENDS TO ADVANCE ELX-02 INTO
PIVOTAL
TRIAL FOR THE TREATMENT OF ALPORT SYNDROME WITH NONSENSE
MUTATIONS FOLLOWING ACHIEVEMENT OF REMISSION IN PATIENT IN PHASE
2 STUDY
* ELOXX PHARMACEUTICALS INC - ELX-02 WELL-TOLERATED IN
STUDY, WITH
NO DISCONTINUATIONS TO DATE
Source text for Eikon: ID:nGNX32J8WL
Further company coverage: ELOX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome